Longeveron Invited to Present at the Benzinga Global Small Cap Conference
Longeveron announced positive Phase 1 study results of Lomecel-B for treating Alzheimer's disease and completed two Phase 2 trials evaluating its safety and efficacy in Aging Frailty subjects. Top-line results from these studies are expected in Q3 2021. The CEO, Geoff Green, will present at the Benzinga Global Small Cap Conference on May 13-14, 2021, highlighting the company's clinical research efforts, including aging-related conditions. Longeveron aims to advance Lomecel-B towards regulatory approval and commercialization.
- None.
- None.
Longeveron recently announced positive results from a Phase 1 study of Lomecel-B in Alzheimer's disease, and the completion of two Phase 2 clinical trials evaluating the safety and efficacy of Lomecel-B infusion in Aging Frailty subjects.
Top-line results from the Aging Frailty studies are anticipated in Q3 2021
MIAMI, May 05, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that Chief Executive Officer Geoff Green will present at the Benzinga Global Small Cap Conference to be held on May 13-14, 2021. Complimentary investor registration can be accessed through the conference link below. In addition to the corporate presentation, Mr. Green is an invited panelist for a session titled “Investing in Longevity Science: The New Drugs & Therapies Designed to Prolong Your Lifespan”, scheduled for Thursday, May 13 at 1:20pm EDT.
| Event registration link: | https://www.benzinga.com/events/small-cap/global/ |
| Presentation date: | May 13, 2021 |
| Presentation time: | 2:10pm - 2:30pm EDT |
| Panel: | Investing in Longevity Science: The New Drugs & Therapies Designed to Prolong Your Lifespan |
| Panel time: | 1:20pm - 1:50pm EDT |
Mr. Green will provide an overview of the Company‘s Aging Frailty clinical research, which spans four clinical programs in the United States, Japan and The Bahamas, and other indications including Alzheimer’s disease.
Designed to bridge the gap between small-cap publicly traded companies, investors and traders, the Benzinga Global Small Cap Conference enables executive leadership of small-cap biotech companies to network and communicate with a broad and diverse investor base in a virtual setting.
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company’s lead investigational product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The Company’s mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community. Additional information about the Company is available at www.longeveron.com.
Forward-Looking Statements
Certain statements in this press release that are not historical facts are forward-looking statements that reflect management's current expectations, assumptions, and estimates of future performance and economic conditions, and involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as "believe," "expects," "may," "looks to," "will," "should," "plan," "intend," "on condition," "target," "see," "potential," "estimates," "preliminary," or "anticipates" or the negative thereof or comparable terminology, or by discussion of strategy or goals or other future events, circumstances, or effects. Moreover, forward-looking statements in this release include, but are not limited to, statements about the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results; the timing and focus of our ongoing and future preclinical studies and clinical trials; the size of the market opportunity for our product candidates, the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates; our ability to obtain and maintain regulatory approval of our product candidates, our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and our ability to avoid infringing the intellectual property rights of others. Further information relating to factors that may impact the Company's results and forward-looking statements are disclosed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Investor Contact:
Brendan Payne
Stern Investor Relations
Office Direct: 212-698-8695 | Office Main: 212-362-1200
brendan.payne@sternir.com | www.sternir.com
Source: Longeveron Inc
Source: LGVN
FAQ
What are the key results of the Phase 1 study of LGVN's Lomecel-B?
When will the top-line results from the Aging Frailty studies be announced for LGVN?
What is Longeveron's participation in the Benzinga Global Small Cap Conference?
What is Lomecel-B and its significance to LGVN?
What conditions are being studied in LGVN's clinical trials?
